

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED
東瑞製藥(控股)有限公司*

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2348)

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

This announcement is made by Dawnrays Pharmaceutical (Holdings) Limited (the “Company”, together with its subsidiaries, collectively the “Group”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”).

The board of the directors (the “Board”) of the Company is pleased to announce that Mr. Hu Shuo (“Mr. Hu”) has been appointed as a non-executive director of the Company with effect from 1 August 2025.

Mr. Hu Shuo (former name: Hu Chunyun), aged 49, obtained his master’s degree in business administration from Guizhou University. Mr. Hu is a director and general manager of Shanghai Jianxin Capital Management Co., Ltd. and a director of Hong Kong Jianxin Group Company Limited. He also serves as the vice president of Zhong Jianxin Holdings Group Co., Ltd. and the vice president of Jinggong Holding Group Co., Ltd. Mr. Hu has more than 20 years working experience in the field of equity investment and mergers and acquisitions transactions and accumulated rich practical experience. Mr. Hu was awarded the honor of Outstanding Talent of Chunshen Pyramid in Minhang District, Shanghai in 2024.

As at the date of this announcement, Mr. Hu has confirmed that he (i) does not hold any positions in the Company and its subsidiaries; (ii) did not hold in the last three years other directorships in any public companies the securities of which are listed on any securities market in Hong Kong or overseas, nor any other major appointments.

As at the date of this announcement, Mr. Hu has confirmed that he is not interested or deemed to be interested in any shares or underlying shares or debentures of the Company or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, Mr. Hu has confirmed that he does not have any relationships with any directors, senior management, substantial shareholders or controlling shareholders of the Company.

Mr. Hu has entered into a letter of appointment with the Company for a term of two years which commences on 1 August 2025 and is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the articles of association of the Company. His appointment may be terminated by either party on not less than one month’s written notice. Under

the terms of his letter of appointment, Mr. Hu will be entitled to an annual remuneration of HK\$300,000 or such other sum that the Board may from time to time decide which is determined based on prevailing market practice, his duties, responsibilities, contribution to the Company and the remuneration of other non-executive director of the Company.

Based on the best information and knowledge of the Board having made all reasonable enquiries and the confirmation from Mr. Hu, there is no information, other than those set out above, that needs to be disclosed pursuant to any of the requirements as set out in Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there is no other matter that needs to be brought to the attention of holders of securities of the Company in connection with the appointment of Mr. Hu.

The Board would like to express its warmest welcome to Mr. Hu for joining the Board.

By Order of the Board
Dawnrays Pharmaceutical (Holdings) Limited
Li Kei Ling
Chairman

Hong Kong, 31 July 2025

As at the date of this announcement, the Board of the Company comprises two executive directors, namely Ms. Li Kei Ling and Mr. Hung Yung Lai; one non-executive director, namely Mr. Leung Hong Man; three independent non-executive directors, namely Mr. Lo Tung Sing Tony, Mr. Ede, Ronald Hao Xi and Ms. Lam Ming Yee Joan.

** for identification purpose only*